Episode 11 – Interview with Dr. Donald Arnold, lead for the CONCOR-1 trial

Welcome back Rounds Table Listeners!

This week we interview Dr. Donald Arnold, a McMaster University professor and hematologist who is leading the CONCOR-1 trial.

The CONvalescent Plasma for COVID-19 Research Trial (CONCOR-1), is a North American clinical trial designed to evaluate the efficacy and safety of COVID-19 convalescent plasma as a therapy for patients with COVID-19 respiratory illness.

It involves collecting plasma containing neutralizing antibodies from individuals who have recovered from the infection and transfusing it to patients with acute COVID-19 infection.

You can find out more information about the CONCOR-1 trial here:

Questions? Comments? Feedback? We’d love to hear from you.

Leave a Comment

Your email address will not be published. Required fields are marked *

  • Susan Saranchuk says:

    Very Interesting and exciting. Unfortunately, the most I can do for Dr. Arnold is cross my fingers, which I have done. Working while I was listening so I might have missed it, but how long does this study last?

  • Nancy says:

    Great session. So good to learn about Dr. Arnold’s fascinating study.


Michael Fralick

Co-director of the Rounds Table

Michael Fralick is a general internist at Mount Sinai Hospital in Toronto. He completed a Master of Science in Clinical Epidemiology at Harvard University, including a Research Fellowship in Health Policy at the Program On Regulation Therapeutics and Law (PORTAL). His PhD focused on the intersection between machine learning and pharmacoepidemiology.

John Fralick


John Fralick is a general internist at Foothills Medical Centre in Calgary. He completed a Master of Science in Epidemiology at Queen’s University. He completed medical school at the University of Calgary and did his internal medicine training at the University of Toronto.

Donald Arnold